<DOC>
	<DOCNO>NCT03077048</DOCNO>
	<brief_summary>Supplementation ketoanalogues essential amino acid improve protein quality protein restrict diet without burden kidney . The ketoanalogues transaminate aminotransferase correspond amino acid incorporate nitrogen amino group derive endogenous amino acid degradation . Therefore , less nitrogen need excrete kidney 's workload reduce . The purpose trial investigate impact Ketosteril® supplementation A ) nutritional safety tolerance low protein diet ( LPD ) ( 0.6 g protein/kg bodyweight ( BW ) /day ) B ) net protein synthesis pre-dialysis CKD patient . Changes urea serum urine assess control metabolic balance condition non-dialysed CKD patient consume LPD supplement Ketosteril® 1 tablet/5 kg body weight/day compare , isonitrogenous isocaloric diet without Ketosteril® . Changes protein synthesis degradation define protein intake without Ketosteril® supplementation investigate - base nitrogen balance , normalized protein catabolic rate well blood level define protein surrogate marker net protein synthesis anabolic signaling .</brief_summary>
	<brief_title>Short-term Metabolic Effects Ketosteril® Supplemented Low Protein Diet Pre-dialysis Chronic Kidney Disease ( CKD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Written inform consent 2 . Nondialysed male female CKD patient expect start dialysis ≥ 3 month 3. eGFR ≥10 &lt; 25 ml/min/1.73 m2 4 . Stable renal function least 12 week enrollment , define change serum creatinine ≤ 40 µmol/L 5 . Body mass index ( BMI ) : ≥ 22 kg/m² ≤ 35 kg/m2 6 . Age : ≥ 40 ≤ 75 year 7 . Eligible physical status patient participation study upon assessment investigator base medical history , physical examination clinical laboratory parameter 1 . Existing gastrointestinal disease pathological finding ( e.g . heart , liver , lung failure ) , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient ( e.g . persistent frequent episode anorexia , vomit , diarrhea ) 2 . Active cancer 3 . Diabetes type I , diabetes type II 4 . HbA1c ≥ 48 mmol/mol , and/or fast blood glucose ≥ 126 mg/dl ( ≥ 7 mmol/L ) ) 5 . Evidence chronic acute infection inflammatory disease 6 . Creactive protein ( CRP ) &gt; 20 mg/L determine screen examination 7 . Known allergic reaction active ingredient use constituent pharmaceutical preparation 8 . Severe allergy multiple drug allergy judge relevant clinical trial investigator 9 . Patients suffer hypercalcaemia serum calcium ≥ 2.9 mmol/L perform screen examination 10 . Major disorder amino acid metabolism , e.g . hereditary disease 11 . Hospitalization within previous 1 month 12 . Proteinuria &gt; 3 g/day 13 . Regular intensive exercise 14 . Ingestion creatine supplement within previous 1 month 15 . Intake anabolic anti catabolic agent within previous 1 month 16 . Any change chronic medication within 1 month screen 17 . Autosomal dominant polycystic kidney disease ( ADPKD ) 18 . Positive antiHIVtest ( positive verify western blot ) , Hepatitis B surface antigen ( HBsAG ) test ( positive verify test hepatitis B core antigen ( HBc ) Immunoglobulin M ( IgM ) ) antihepatitis C virus ( HCV ) test 19 . Current drug alcohol dependence 20 . Blood donation ( include donation plasma platelet ) blood loss 400 ml within last 2 month prior individual enrolment patient 21 . Participation interventional clinical trial last 2 month prior individual enrolment patient 22 . Patients report frequent occurrence migraine attack ( i.e . least per month ) 23 . History relevant central nervous system ( CNS ) and/or psychiatric disorder and/or currently treat CNS and/or psychiatric disorder 24 . Change habits physical activity within last 2 month least 7 day ( e.g . immobilisation due bed rest , immobilisation leg big muscle group ) 25 . Positive pregnancy test screen examination 26 . Pregnant lactate woman 27 . Not willing apply highly effective contraceptive method [ i.e . combine ( estrogen progestogen contain ) hormonal contraception e.g . oral , intravaginal , transdermal progestogenonly hormonal contraception e.g . oral , injectable , implantable well intrauterine device ( IUD ) intrauterine hormonereleasing system ( IUS ) combination male condom ; bilateral tubal occlusion , vasectomise partner sexual abstinence ] 28 . Patients suspect know follow instruction 29 . Patients unable understand write verbal instruction , particular regard risk inconvenience expose participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CKD</keyword>
	<keyword>Ketosteril</keyword>
	<keyword>keto-acids</keyword>
	<keyword>ketoanalogues</keyword>
	<keyword>Chronic kidney disease</keyword>
</DOC>